Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Prokarium logo — LIVING CURES

Prokarium

LIVING CURES

Founded 2012 United Kingdom London, United Kingdom 16 employees Total: $80.90M Biotechnology, Health Care +1

General Information

Company Name Prokarium
Founded Year 2012
Location United Kingdom London, United Kingdom
Employees 16
Industries Biotechnology, Health Care, Pharmaceutical
Business Model B2B, B2D, B2G
Revenue Model Licensing, Product Sales, Performance Based
Social

BounceWatch is an independent company data service, not affiliated with Prokarium. To contact Prokarium, visit prokarium.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Prokarium compare?

A PDF of Prokarium and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Prokarium soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Prokarium

Prokarium, founded in 2012 and headquartered in the United Kingdom, is carving a niche in the innovative field of microbial immunotherapy. With the slogan "LIVING CURES," the company is developing cutting-edge treatments that harness recent advances in cancer immunology to revolutionize immuno-oncology.

Their lead program particularly targets bladder cancer, aiming to set a new benchmark in treatment paradigms through orchestrated, immune-driven, and enduring antitumor effects. By focusing on these advancements, Prokarium positions itself at the forefront of the biotechnology and pharmaceutical industries.

Most recently, the company secured a $6.28M Convertible Note investment on 01 December 2025 from NVEST VENTURE. This injection of capital underscores strong investor confidence in the company's potential to deliver transformative healthcare solutions and further expand its innovative pipeline.

Business keywords: Microbial Immunotherapy, Immuno-Oncology, Bladder Cancer Treatment, Cancer Immunology, Biopharmaceutical, Synthetic Biology, Vaccine Development, Oral Delivery Systems, Immune-Driven Antitumor Effects, Oncology Therapeutics, Cancer Treatment Paradigm, Long-Lasting Immunotherapy, Re-engineered Evolution, Cancer Immunotherapy, Biotechnology Platform

Services & Products

Development of novel immunotherapies
Research and development of bacterial-based treatments for cancer
Discovery and clinical trial activities

Target Customers

Pharmaceutical companies Biotechnology firms Oncology researchers Cancer treatment centers

Funding Rounds & Investors (10)

View All
Funding Stage Amount Investors Lead Investors Date
Convertible Note $6.28M 1
NVEST VENTURE
NVEST VENTURE
01 Dec 2025
Grant £320.00K 1
UK Research and Innovation
UK Research and Innovation
01 Aug 2024
Late VC $30.00M -
01 Feb 2023
Series B $21.00M 4
Korea Investment Partners Future Fund Riyadh Valley Co
Korea Investment Partners, Future Fund +2
01 Oct 2020
Early VC £4.90M 1
Wellcome Trust
Wellcome Trust
01 Oct 2019
Early VC €8.00M 3
Korea Investment Partners Riyadh Valley Co NVEST VENTURE
Korea Investment Partners, Riyadh Valley Co +1
01 Feb 2018
Grant £2.00M -
01 Jul 2016
Round Undisclosed 1
SynbiCITE
01 Aug 2015
Grant £400.00K 1
Biotechnology and Biological Sciences Research Council (BBSRC)
01 Mar 2013
Seed $8.00M 1
NVEST VENTURE
NVEST VENTURE
01 Jan 2012

Prokarium Alternatives & Competitors

View All Alternatives
Prokarium vs
Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc. United States

Focused on harnessing the immune system to achieve deep and durable clinical responses to improve th...

Post-IPO Equity
96 employees
Biopharma, Biotechnology
Compare Prokarium vs Xilio Therapeutics, Inc.
Prokarium vs
Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. United States

Plans to develop a novel format for T-cell mediated anti-tumour therapy

IPO
47 employees
Biotechnology, Pharmaceutical
Prokarium vs
Macomics
Macomics United Kingdom

Macrophage Biology Revealed:Developing breakthrough approaches to macrophage activity to change the...

Series A
24 employees
Biotechnology, Health and Wellness
View all alternatives

FAQ About Prokarium

LIVING CURES
Prokarium was founded in 2012.
Prokarium is headquartered in London, United Kingdom.
Prokarium operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on Microbial Immunotherapy, Immuno-Oncology, Bladder Cancer Treatment and Cancer Immunology. Its customers include Pharmaceutical companies, Biotechnology firms and Oncology researchers.
Prokarium has a B2B, B2D and B2G business model. Its revenue comes from Licensing, Product Sales and Performance Based.
Prokarium has approximately 16 employees.
Prokarium has completed 10 funding rounds, raising a total of $80.90M.
Prokarium offers: Development of novel immunotherapies, Research and development of bacterial-based treatments for cancer, Discovery and clinical trial activities.
Top alternatives and competitors to Prokarium include Xilio Therapeutics, Inc., Bolt Biotherapeutics, Inc., Macomics, Brenus Pharma, Persephone Biosciences. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Prokarium and Xilio Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Prokarium, https://bouncewatch.com/company/prokarium, updated 26 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes